A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future.
BACKGROUND
Among the 5-HT(1B/1D) agonists or 'triptans,' which are considered first-line therapy for acute migraine, rizatriptan has emerged as one of the most efficacious.


OBJECTIVE
Several comprehensive reviews of rizatriptan are available in the literature; the aim of this paper is to review the most current research with rizatriptan.


METHODS
The scope of the review addresses current topics of clinical interest, including studies of time to pain relief, effect of early administration, use in combination with other drugs, and tolerability updates, as well as trials of rizatriptan in certain subpopulations such as patients with menstrual migraine, patients with motion sickness and pediatric patients.


CONCLUSIONS
In the context of these newly available data, the potential for expansion of the role of rizatriptan in the clinic is evaluated.
Mannix
Lisa K
LK
Headache Associates and ClinExcel Research 7908 Cincinnati-Dayton Road Suite J, West Chester, OH 45069, USA. LKMannixMD@aol.com
D000328:Adult; D002648:Child; D004359:Drug Therapy, Combination; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D058825:Serotonin 5-HT1 Receptor Agonists; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014363:Tryptamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D058825:Serotonin 5-HT1 Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan